CannabisLink.ca - Current Affairs 2026

(2026) - Chronological (1515 items)

(All links open in new tab)

Sep 14, 2026	Curaleaf asks Alberta regulator to halt Aurora's share issuances while its offer stands Curaleaf has filed an application with the Alberta Securities Commission seeking to stop Aurora Cannabis from issuing shares under its at-the-market program for as long as Curaleaf's offer for the company remains outstanding. The application asks the commission to halt further issuances immediately and to protect the ability of Aurora shareholders to consider and respond to the offer, and Curaleaf has requested an expedited hearing. It follows Curaleaf's formal offer for all issued and outstanding Aurora shares, commenced on 19 August at 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash per Aurora share, which the company values at approximately US$4.00, and Aurora's rejection of it.
Sep 14, 2026	Report: Cannabis Excise Taxes Totaled Over $3.5 Billion Across 30 U.S. States Last Year Locally licensed cannabis retailers in 30 U.S. states and the District of Columbia generated about $3.55 billion in cannabis excise tax revenues between July 2025 and June 2026, according to a U.S. Census report.
Sep 14, 2026	Cayman Islands Considers Cannabis Reform Options Government officials in the Cayman Islands, a self-governing British Overseas Territory located in the western Caribbean Sea, are reviewing public responses regarding proposed changes to current cannabis laws. The public submitted responses during a two-month consultation period. On July 1st, 2026, the Cayman Islands government published its “Cannabis Reform: Options for a Harm Minimisation Framework” discussion paper, which included various options to consider for modernizing current cannabis laws. The public consultation period ended on September 1st.
Sep 14, 2026	Bill Directing Federal Health Officials To Track Testing For Marijuana And Other Drugs In Hospital ERs Set For House Vote This Week The U.S. House of Representatives is expected to vote on a bill this week to require the Department of Health and Human Services (HHS) to study how prevalent drug testing for marijuana, fentanyl and other drugs is in hospital emergency departments.
Sep 14, 2026	Cannabis: do workplaces have a problem with ‘drug thinking’? A laboratory can answer the wrong question perfectly. An employee provides a sample. The result is positive for cannabis. The analysis may be technically sound, the chain of custody secure and the paperwork satisfyingly complete. But what, exactly, has the test shown? That has become harder to answer since 2018, when certain cannabis-based products for medicinal use were moved into Schedule 2 of the Misuse of Drugs Regulations, creating a lawful route to prescription. Recreational cannabis did not become legal. Yet cannabis can now sit, depending on context, on both sides of a workplace ‘drug’ policy: prescribed medicine and illicit drug. The Care Quality Commission reported a 130% rise in private prescription items for unlicensed cannabis-based medicinal products between 2022-23 and 2023-24. Those are prescription items, not patients, but the rise makes medical cannabis increasingly difficult for employers to regard as marginal.
Sep 12, 2026	Can Exercise Get You High? The Surprising Link Between Cannabis and Exercise The research over the last decade has been diving deeper into cannabis use and its effects on the body and mind. Some studies have even found surprising correlations between the euphoric feeling during exercise—sometimes referred to as a runner’s high—and how your body reacts to cannabis. That high can feel like a change in mood to straight up euphoria. And as it turns out, it is the result of activation of the endocannabinoid system—cannabis-like substances that our bodies produce naturally.
Sep 11, 2026	What Massachusetts Cannabis Consumers Need to Know About Question 8, The Ballot Measure To Roll Back Legalization (Op-Ed) If you are a Massachusetts voter who has not been following the debate over cannabis policy, Question 8 on this November’s ballot deserves your attention. The measure asks voters whether Massachusetts should repeal the laws that allow and regulate adult-use cannabis sales. The implications go well beyond whether a dispensary remains open. The question reaches the system of licensed businesses, product testing, taxation and regulatory oversight that Massachusetts has built over the past decade—seeking to eliminate 27,000 jobs and $300,000,000 in tax revenue that will need to be made up somewhere else.
Sep 11, 2026	Positive Early Results for Dutch Cannabis Supply Chain Pilot The Netherlands’ experiment to introduce regulated cannabis into its coffeeshop system is going well, despite some growing pains, according to the first follow-up study after the program launched in 2025. The Dutch Government launched its Controlled Cannabis Supply Chain Experiment in April 2025, as part of a plan for a “closed cannabis chain” for dozens of cannabis coffeeshops in ten cities across the country. The experiment is planned to continue through the end of 2029, with the goal of better understanding how to fully regulate cannabis sold in the Netherlands.
Sep 11, 2026	Mexico’s Supreme Court allows home cannabis edibles, but with a limited practical effect Mexico’s Supreme Court has ruled that people with personal recreational cannabis authorizations can now make marijuana-infused edibles for their own personal use — but people still cannot legally buy or sell them. The ruling — which applies to gummies, brownies and other homemade edibles laced with cannabis — expands what the Federal Commission for Protection against Sanitary Risks (Cofepris) must allow under an authorization for adult recreational self-consumption.
Sep 11, 2026	What Curaleaf’s hostile takeover bid for Aurora Cannabis is really about First, this is not a $4 cash offer. Aurora shareholders would receive $0.75 in cash and 0.3463 Curaleaf subordinate voting shares for each Aurora share. When Curaleaf announced the bid, that package was worth approximately $4. But its value changes with Curaleaf’s stock price, which during trading Thursday afternoon was hovering around $10.09 per share on over-the-counter markets. Despite announcing intentions to uplist to a major exchange in May, Curaleaf remains listed on OTC. If Curaleaf’s stock falls, Aurora shareholders receive less. If Curaleaf’s stock rises far enough, the exchange ratio is reduced so that the total consideration does not exceed $5 per share. Aurora shareholders are exposed to the decline, but their upside stops at $5. The cash portion deserves a closer look.
Sep 10, 2026	Avicanna Launches New Integrated Health Program to Expand Medical Cannabis in Clinical Settings Medical cannabis company Avicanna Inc. has launched a new program to support healthcare organizations looking to incorporate medical cannabis into their existing models of care. The Toronto-based company is expanding its MyMedi.ca platform as part of its new Integrated Health Program, designed to integrate medical cannabis care and patient support into Canadian healthcare institutions and clinical networks. The new program builds on Avicanna’s existing MyMedi.ca platform, a medical cannabis care infrastructure to better serve medical cannabis patients’ needs.
Sep 10, 2026	Nebraska Supreme Court Reaffirms Validity of State’s Medical Marijuana Laws Nebraska’s highest court has upheld a pair of voter-endorsed medical marijuana measures, dismissing a legal effort that argued that fraud tainted the petition campaign that placed them before voters in 2024. In a unanimous 7-0 ruling, Jeffrey Funke, the Chief Justice, said a Lancaster County judge was correct to conclude that supporters had gathered sufficient valid signatures. The 49-page decision rejected claims brought by John Kuehn, a former senator in the state and a vocal critic of medical cannabis, along with arguments advanced by state AG Mike Hilgers and Bob Evnen, the Secretary of State.
Sep 10, 2026	Wisconsin Is Ready To Legalize Marijuana Next Year Under Democratic Or GOP Control, Congressman Says A Democratic congressman who represents Wisconsin says the state is poised to legalize marijuana as soon as next year—especially if his party wins control of the legislature in the November elections, but perhaps even if Republicans maintain a majority under new leadership for the 2027 session. Rep. Mark Pocan (D-WI) told Marijuana Moment that there’s a “really good chance” of legalizing cannabis in Wisconsin in the short term if Democrats can “flip the legislature,” where marijuana reform proposals have stalled under Republican control in recent sessions.
Sep 10, 2026	A Magazine From 1969 Made the Case the DEA Is Making Now. It Also Named the People Who Would Spend 57 Years Stalling. The government’s closing brief in the marijuana rescheduling hearing was filed on August 17, 2026. It argues that cannabis has an accepted medical use, that the evidence has been sitting there for years, and that the people insisting the science isn’t ready yet are applying a standard the law does not require. Somebody made that argument first, on newsprint, for fifty cents, in the winter of 1969. The magazine was called The Marijuana Review. Volume one, number two, dated January through March 1969, twenty-four pages, published by an outfit called LeMar International out of Box 71, Norton Hall, at the State University of New York at Buffalo. LeMar was short for Legalize Marijuana. The editors listed on page 3 are Mike Aldrich and Ed Sanders. Under a heading reading “consultant gurus,” the first name is Allen Ginsberg.
Sep 10, 2026	CBD Helps Athletes Recover From Exercise But Does Not Boost Performance, Study Shows The cannabis component CBD “supports post-exercise recovery” for athletes “but does not directly enhance performance,” according to a new scientific review. Cannabidiol “demonstrates efficacy in modulating delayed-onset muscle soreness (DOMS) and lowering concentrations of muscle damage markers (creatine kinase and myoglobin), particularly within the 48-72 hour window following intensive exercise,” the paper, published in the International Medical Journal, found.
Sep 10, 2026	New Orleans’ French Quarter gets its first-ever marijuana dispensary. ‘I’m speechless.’ A brass band, feathered showgirls and brightly beaded Mardi Gras Indians brought the party to Bourbon Street on Wednesday morning, but it wasn’t for a wedding or a bachelor party — or anything to do with boozing on New Orleans’ most popular path for partygoers. The French Quarter’s first-ever cannabis dispensary opened its doors to customers in a 100-year-old building at 433 Bourbon St., offering three stories of edibles, vapes, cannabis flower as well as features like a third-floor gallery, theater experience and terpene smell bar.
Sep 10, 2026	Legalization Nation: Media misleading readers about cannabis safety – again Legalization Nation talks about cannabis from a ground-level perspective, addressing issues like the traditional market, patients’ rights, corporate advantage, and more, and compares state cannabis legalization policies to help make sense of a daunting landscape through a familiar medium.
Sep 9, 2026	Campaign to criminalize Massachusetts cannabis sales heavily outspending opposition The national anti-cannabis advocacy group behind the effort to convince voters to recriminalize the state’s $1.6 billion annual adult-use marijuana industry is outspending industry supporters by a more than 2-to-1 margin, campaign finance records show. Through the end of August, SAM Action Inc., the political arm of legalization foe Smart Approaches to Marijuana, has committed nearly $3.2 million to the so-called Coalition for Healthy Massachusetts.
Sep 9, 2026	New Review Challenges Evidence Behind Cannabis ‘Entourage Effect’ A comprehensive new review dives into the available research looking at the entourage effect for cannabis. This “entourage effect” is at the heart of the argument for why full-spectrum products are frequently presented as more medically effective than single-molecule pharmaceuticals like dronabinol, something cannabis consumers often echo through personal experience. First introduced in 1998 by Dr. Raphael Mechoulam and Dr. Shimon Ben-Shabat, the popular theory that whole-plant products offer superior medical outcomes and enhanced tolerability over isolated THC has become a foundational narrative shaping patient advocacy and commercial market strategy within the cannabis sector. However, the new review published in Current Neuropharmacology suggests that the scientific reality of these phytochemical interactions is far more complex, and often less conclusive, than popular consensus might sometimes imply.
Sep 9, 2026	CT cannabis company continues hostile takeover fight with Canadian rival Stamford-based cannabis giant Curaleaf Holdings has fired the latest salvo in its hostile takeover fight with Canadian company Aurora Cannabis. Curaleaf announced in August that it intended to acquire Aurora Cannabis for $4 per share, saying the proposal represented a 45% premium to Aurora’s 30-day average share price. The company said at the time it had initially approached Aurora privately in June and followed up in July after the Canadian company declined to engage.

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76